DOI:
10.1055/s-00034612
Yearbook of Medical Informatics
LinksClose Window
References
Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L. et al.
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomized, open-label phase 3 study (KEYNOTE-006).
Lancet 2017;
390 10105 1853-62
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.